Reasons for Visits to the Dermatologist Stratified by Race.

OBJECTIVES: The aim of this study was to examine, from the patient's perspective, the most common reasons for seeking medical attention for skin disease and how this varies among different races. METHODS: We conducted a cross-sectional analysis on the National Ambulatory Medical Care Survey between 2007 and 2018, the most recent years available. The frequency of each reason for visits was determined using the survey procedures of SAS version 9.4. RESULTS: Among White patients, skin cancer screening (8.2%) was the most common reason for visits followed by skin lesions (7.8%) and discoloration/abnormal pigmentation (7.4%). Among Blacks/African Americans, acne (9.2%), progress visit (8.2%), and skin rash (7.0%) were the top reasons for visits. Acne (12%), skin rash (7.5%), and discoloration/abnormal pigmentation (7.3%) were the most common reasons for patient visits in the "other" race category. CONCLUSIONS: Reasons for visits to the dermatologist vary with race. White patients appear to be aware of their increased risk of skin cancer, visiting frequently for skin cancer screenings and skin lesions, whereas Blacks/African Americans are more affected by conditions associated with chronic pruritus. To train dermatologists and nondermatologists to provide equitable care for cutaneous conditions to all races and skin types, especially for those groups experiencing barriers to receiving dermatologic care, it is important that we characterize the reasons why patients visit the dermatologist.

Why Do Patients in the United States Seek Care from Dermatologists?

INTRODUCTION: While the diagnoses made at visits to the dermatologist are well characterized, the reasons patients visit the dermatologists are not well described. Understanding why patients present to dermatologists could be helpful in identifying patients' unmet needs and developing outreach programs to improve patients' access to care. The purpose of this study is to characterize the reasons why US patients sought medical attention from dermatologists. METHODS: We evaluated the National Ambulatory Medical Care Survey (NAMCS) between 2007 and 2018, the most recent years available, to characterize the most common reasons patients visit the dermatologist. RESULTS: Sixty-four thousand records were identified in the NAMCS estimating 1.55 billion visits to the dermatologist in the US during the study period. The most common reasons for visits were skin examination (7.8%), skin lesion (7.5%), and discoloration/abnormal pigmentation (7.3%). For patients ≤ 18 years, the most common reasons for visits were acne (28%), warts (7.7%), and skin rash (6.4%). For patients 19-65 years and ≥ 66 years, skin examinations (7.7%) and skin lesions (10%) were the most common reasons for visits to dermatologists, respectively. CONCLUSION: By identifying the most common reasons for visits to the dermatologist, we can improve our understanding of a patient's needs and appropriate health outreach resources to improve patients' access to care.

Skin conditions affect 1.9 billion people globally. While we understand the most common diagnoses made at a dermatology visit, the reasons why patients visit the dermatologist have not been evaluated. We utilized an annual survey conducted by the Centers for Disease Control and Prevention (CDC), the National Ambulatory Medical Care Survey (NAMCS), to identify the most common reasons patients visited the dermatologist between the years 2007 and 2018, the most recent years of the survey available. The most common reasons for visits were skin examination, skin lesion, and discoloration/abnormal pigmentation. For patients ≤ 18 years, the most common reasons for visits were acne, warts, and skin rash. For patients 19­65 years and ≥ 66 years, skin examinations and skin lesions were the most common reasons for visits to dermatologists, respectively. By identifying the most common reasons for visit to the dermatologist, we can better understand a patient's needs and improve a patient's ability to access care for skin conditions.

Methotrexate and Patch Testing: A Retrospective Review.

BACKGROUND: Patch testing while taking systemic immunosuppressants is sometimes unavoidable. Methotrexate (MTX) is the immunosuppressant currently considered least likely to negatively impact patch testing. OBJECTIVE: The aim of the study was to characterize a cohort of patients patch tested while taking MTX. METHODS: This is a retrospective review of patients patch tested at the University of North Carolina Dermatology in Chapel Hill, North Carolina, from 2010 to 2019, comparing patch test results of patients taking MTX with those of a control group. RESULTS: An overall 52.8% positivity rate (356/674) was observed. Sixty two of 674 patients were patch tested while taking MTX, with a 46.8% positivity rate (29/62) compared with 53.4% (327/612) in the control group. The control group experienced 975 reactions, including 637 1+ reactions, 291 2+ reactions, and 47 3+ reactions. The MTX group experienced 50 reactions, including thirty-two 1+ reactions, fourteen 2+ reactions, and four 3+ reactions. The difference between the distributions was not statistically significant. Mean weekly MTX dose was 15.6 mg, whereas mean total accumulated dose was 251.6 mg. There was no statistically significant difference between weekly dose and total accumulated dose in patients with positive or negative results. CONCLUSIONS: In our cohort, MTX had no discernible effect on patch test results, supporting use during patch testing with minimal false-negative risk.